Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2011 5
2012 1
2013 3
2014 6
2015 6
2016 4
2017 5
2018 9
2019 8
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Results by year
Filters applied: . Clear all
Page 1
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
Gelsomino F, Lamberti G, Parisi C, Casolari L, Melotti B, Sperandi F, Ardizzoni A. Gelsomino F, et al. Cancer Treat Rev. 2019 Sep;79:101887. doi: 10.1016/j.ctrv.2019.08.003. Epub 2019 Aug 8. Cancer Treat Rev. 2019. PMID: 31491661 Review.
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
Cinausero M, Laprovitera N, De Maglio G, Gerratana L, Riefolo M, Macerelli M, Fiorentino M, Porcellini E, Buoro V, Gelsomino F, Squadrilli A, Fasola G, Negrini M, Tiseo M, Ferracin M, Ardizzoni A. Cinausero M, et al. Among authors: gelsomino f. Ther Adv Med Oncol. 2019 Nov 14;11:1758835919885540. doi: 10.1177/1758835919885540. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31798692 Free PMC article.
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
Mazzaschi G, Facchinetti F, Missale G, Canetti D, Madeddu D, Zecca A, Veneziani M, Gelsomino F, Goldoni M, Buti S, Bordi P, Aversa F, Ardizzoni A, Quaini F, Tiseo M. Mazzaschi G, et al. Among authors: gelsomino f. Lung Cancer. 2019 Jan;127:153-163. doi: 10.1016/j.lungcan.2018.11.038. Epub 2018 Nov 29. Lung Cancer. 2019. PMID: 30642544
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer.
Landi L, D'IncĂ  F, Gelibter A, Chiari R, Grossi F, Delmonte A, Passaro A, Signorelli D, Gelsomino F, Galetta D, Giannarelli D, Soto Parra H, Minuti G, Tiseo M, Migliorino MR, Cognetti F, Toschi L, Bidoli P, Piantedosi F, Calabro' L, Cappuzzo F. Landi L, et al. Among authors: gelsomino f. J Immunother Cancer. 2019 Nov 21;7(1):316. doi: 10.1186/s40425-019-0793-8. J Immunother Cancer. 2019. PMID: 31752994 Free PMC article.
Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
Gelsomino F, Di Federico A, Filippini DM, Dall'Olio FG, Lamberti G, Sperandi F, Balacchi C, Brocchi S, Ardizzoni A. Gelsomino F, et al. Clin Lung Cancer. 2020 Mar;21(2):e45-e48. doi: 10.1016/j.cllc.2019.11.011. Epub 2019 Nov 20. Clin Lung Cancer. 2020. PMID: 31902695 No abstract available.
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
Grossi F, Genova C, Crinò L, Delmonte A, Turci D, Signorelli D, Passaro A, Soto Parra H, Catino A, Landi L, Gelsomino F, Tiseo M, Puppo G, Roila F, Ricciardi S, Tonini G, Cognetti F, Toschi L, Tassinari D, Scoppola A, Giannarelli D, Cortesi E. Grossi F, et al. Among authors: gelsomino f. Eur J Cancer. 2019 Dec;123:72-80. doi: 10.1016/j.ejca.2019.09.011. Epub 2019 Oct 28. Eur J Cancer. 2019. PMID: 31671314
Immune-mediated cholangitis: is it always nivolumab's fault?
Gelsomino F, Vitale G, Ardizzoni A. Gelsomino F, et al. Cancer Immunol Immunother. 2018 Aug;67(8):1325-1327. doi: 10.1007/s00262-018-2159-3. Epub 2018 Apr 5. Cancer Immunol Immunother. 2018. PMID: 29623342 No abstract available.
DARPP-32 and t-DARPP isoform in non-small cell lung cancer (NSCLC): could they drive patients' clinical management and be a therapeutic target?
Lamberti G, Peterle C, Gelsomino F. Lamberti G, et al. Among authors: gelsomino f. Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S326-S328. doi: 10.21037/tlcr.2018.12.06. Transl Lung Cancer Res. 2018. PMID: 30705846 Free PMC article. No abstract available.
MET and Small-Cell Lung Cancer.
Gelsomino F, Rossi G, Tiseo M. Gelsomino F, et al. Cancers (Basel). 2014 Oct 13;6(4):2100-15. doi: 10.3390/cancers6042100. Cancers (Basel). 2014. PMID: 25314153 Free PMC article. Review.
The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer.
Ciccarese C, Nobili E, Grilli D, Casolari L, Rihawi K, Gelsomino F, Tortora G, Massari F. Ciccarese C, et al. Among authors: gelsomino f. Expert Rev Anticancer Ther. 2016 Jul;16(7):681-96. doi: 10.1080/14737140.2016.1192468. Epub 2016 Jun 7. Expert Rev Anticancer Ther. 2016. PMID: 27210425 Review.
47 results
Jump to page
Feedback